Lansing Street Advisors’s Corcept Therapeutics CORT Stock Holding History

Lansing Street Advisors’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$67	Hold	3	–	–	﹤0.01%	274
2023 Q1	$65	Hold	3	–	–	﹤0.01%	286
2022 Q4	$61	Hold	3	–	–	﹤0.01%	350
2022 Q3	$0	Hold	3	–	–	﹤0.01%	265
2022 Q2	$0	Hold	3	–	–	﹤0.01%	249
2022 Q1	$0	Buy	+3	New	+$64	﹤0.01%	277

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Lansing Street Advisors's CORT Position: Q2 2023 in Review

Lansing Street Advisors held its Corcept Therapeutics (CORT) position steady in Q2 2023 at 3 shares worth $67. The position accounts for ﹤0.01% of the portfolio, ranked #274.

Lansing Street Advisors first reported a position in CORT in Q1 2022 and has held it in 6 quarters since. 224 funds tracked by Wall St. Rank hold CORT as of Q2 2023.

Lansing Street Advisors held 3 shares of Corcept Therapeutics worth $67 as of Q2 2023.
Lansing Street Advisors left its Corcept Therapeutics share count unchanged in Q2 2023.
Corcept Therapeutics made up ﹤0.01% of Lansing Street Advisors's portfolio in Q2 2023, its #274 holding.
Lansing Street Advisors first reported a position in Corcept Therapeutics in Q1 2022 and has held it in 6 quarters since.
224 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2023.

Based on Lansing Street Advisors's 13F filing for Q2 2023, filed 11 Aug 2023.